A budget impact model and a cost-utility analysis of reducer device (Neovasc) in patients with refractory angina.

ABSTRACT:

Background

Refractory angina (RA) is a chronic condition characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD). Treatments for this condition have undergone major developments in recent decades; however, the treatment for RA remains a challenge for medicine. In this sense, the Coronary Sinus Reducer System (CSRS) stands as the last line of therapy for ineligible patients for revascularization with reversible ischemia. The purpose of this report is to evaluate the potential burden on the National Health Service (NHS) and measure the health effects in terms of both quantity (life years) and quality-of-life aspects related to the reducer.

Methods

Two different economic ev

SUBMITTER: Fortunato A 

PROVIDER: S-EPMC10982321 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature